News

BioCryst Pharmaceuticals has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5m under a newly

Using Catalent’s drug delivery technologies, the two companies will collaborate exclusively to develop certain oral formulations of small-glycol drugs. Oral formulations of synthetic oligosaccharides will allow full exploitation

Helix BioPharma has completed patient enrollment in its phase II trial of Topical Interferon Alpha-2b for the treatment of ano-genital warts (AGW), with the required 120th patient randomized

Under the agreement, Aureus will provide AurSCOPE knowledge databases and continue to update existing databases for Sanofi-Aventis’ R&D division. These databases are expected to give Sanofi-Aventis researchers access

Superior Global Software, has completed the acquisition of assets and business of HTI Technologies, Georgia. Under the terms of the agreement, Superior Global purchased substantially all of the

In newborn screening programs, infants are tested for a range of genetic, metabolic or hematologic disorders. When identified within the first few days of life, these disorders are

DARA BioSciences (DARA) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for US Patent Application No 12/112,213 entitled “Methods for Decreasing or

Nabi Biopharmaceuticals has completed the sale of PentaStaph (Pentavalent S. aureus Vaccine) and related assets to GlaxoSmithKline (GSK), which was announced in August 2009. Under the terms of

NovaRx has received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix phase III clinical trial in patients with non-small cell lung cancer